Cargando…
Combination therapy with brentuximab vedotin and cisplatin/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphoma
Anaplastic large cell lymphoma (ALCL) is a common subtype of the heterogeneous group of peripheral T-cell lymphomas, which is characterized by large pleomorphic cells with strong expression of CD30. Translocations involving ALK, the anaplastic lymphoma kinase gene, are associated with a favorable cl...
Autores principales: | Heidegger, Simon, Beer, Ambros J, Geissinger, Eva, Rosenwald, Andreas, Peschel, Christian, Ringshausen, Ingo, Keller, Ulrich |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4074177/ https://www.ncbi.nlm.nih.gov/pubmed/25018638 http://dx.doi.org/10.2147/OTT.S59795 |
Ejemplares similares
-
Brentuximab Vedotin in Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma
por: Tsang, Vivian
Publicado: (2012) -
Brentuximab vedotin for refractory anaplastic lymphoma kinase-negative anaplastic large cell lymphoma in leukemic phase with RUNX3 overexpression
por: Yamashita, Yusuke, et al.
Publicado: (2020) -
Brentuximab vedotin use in pediatric anaplastic large cell lymphoma
por: Agrusa, Jennifer E., et al.
Publicado: (2023) -
Improvement of Cutaneous Anaplastic Large Cell Lymphoma by Brentuximab Vedotin Monotherapy
por: Onaka, Takashi, et al.
Publicado: (2018) -
Cutaneous Anaplastic Large-Cell Lymphoma with Dramatic Response to Brentuximab Vedotin
por: Şahin, Mustafa, et al.
Publicado: (2021)